- Home
- RMCF vs TENX Comparison
RMCF vs TENX Comparison
Compare RMCF & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCF
- TENX
- Stock Information
- Founded
- RMCF 1981
- TENX 1967
- Country
- RMCF United States
- TENX United States
- Employees
- RMCF N/A
- TENX N/A
- Industry
- RMCF Specialty Foods
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- RMCF Consumer Staples
- TENX Health Care
- Exchange
- RMCF Nasdaq
- TENX Nasdaq
- Market Cap
- RMCF 14.3M
- TENX 11.4M
- IPO Year
- RMCF N/A
- TENX N/A
- Fundamental
- Price
- RMCF $2.19
- TENX $3.39
- Analyst Decision
- RMCF
- TENX Strong Buy
- Analyst Count
- RMCF 0
- TENX 2
- Target Price
- RMCF N/A
- TENX $30.00
- AVG Volume (30 Days)
- RMCF 15.1K
- TENX 29.1K
- Earning Date
- RMCF 10-15-2024
- TENX 11-11-2024
- Dividend Yield
- RMCF N/A
- TENX N/A
- EPS Growth
- RMCF N/A
- TENX N/A
- EPS
- RMCF N/A
- TENX N/A
- Revenue
- RMCF $27,921,687.00
- TENX N/A
- Revenue This Year
- RMCF N/A
- TENX N/A
- Revenue Next Year
- RMCF N/A
- TENX N/A
- P/E Ratio
- RMCF N/A
- TENX N/A
- Revenue Growth
- RMCF N/A
- TENX N/A
- 52 Week Low
- RMCF $1.50
- TENX $2.77
- 52 Week High
- RMCF $5.15
- TENX $61.20
- Technical
- Relative Strength Index (RSI)
- RMCF 70.41
- TENX 42.55
- Support Level
- RMCF $1.95
- TENX $3.28
- Resistance Level
- RMCF $2.04
- TENX $3.54
- Average True Range (ATR)
- RMCF 0.09
- TENX 0.20
- MACD
- RMCF 0.03
- TENX -0.01
- Stochastic Oscillator
- RMCF 83.02
- TENX 26.42
About RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.